Indications -- Asthma/Allergy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Asthma/Allergy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	7/10/2002 10:16:49 AM
From: nigel bates	Read Replies (1) of 86

GSK / elbion / AWD12-281 LONDON, July 10 (Reuters) - Britain's GlaxoSmithKline Plc (GSK) said on Wednesday it had agreed to help develop and commercialise an experimental treatment for nasal allergies and asthma with German drugs company elbion AG. Europe's biggest drugmaker said it would have exclusive worldwide development, registration, manufacturing and commercialisation rights for the drug, codenamed AWD12-281, and would assume all the related costs. GSK will also make an undisclosed upfront payment to elbion, as well as clinical and regulatory milestone payments and a royalty on sales. AWD12-281 is currently in Phase II clinical trials as an intra-nasal treatment of allergic rhinitis -- inflammation of the nasal passages and fluid production caused by allergies to such things as dust mites, pollen, animals or mould. The drug is also in Phase I trials as an inhaled treatment for asthma and chronic obstructive pulmonary disease...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next